Haleon’s New UEFA Medical Deal Puts Voltaren in Football Spotlight—But Shares Lag
Haleon became UEFA Medical’s first Health Partner in a multi-year deal focused on football-related pain management and clinician education. The company’s pain relief sales slipped 0.3% in the first quarter, while respiratory health dropped 3.4%. Haleon shares ended slightly lower in London. Financial terms of the UEFA partnership were not disclosed.